NIFTY 50

Moneycontrol Pro Ideas For Profit: Here’s why Suven Pharma is in focus

Updated : April 08, 2021 12:59:34 IST

Suven Pharma posted strong numbers in the last quarter led by re-initiation of supplies in the CRAMS space. EBITDA margin was at 50 percent which is way higher than peers such as Syngene, Gland Pharma, and Divis Lab.

In the special segment ‘Moneycontrol Pro Ideas For Profit’, moneycontrol.com’s Anubhav Sahu gets more details on how the company is expected to perform going forward.

Watch the video for more.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV

recommended for you